Generex Biotechnology Corporation (NASDAQ: GNBT) today announced presentation of interim results from a Phase II efficacy study of a novel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE